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ABSTRACT
Background. Gastrointestinal (GI) complications are common after renal transplanta-
tion, mainly owing to immunosuppressive therapy. Assessment of GI transit time can
facilitate rational management of these disorders.
Objective. We evaluate the GI transit parameters in renal transplant recipients taking
tacrolimus, azathioprine, and prednisone with the use of the alternate current biosuscep-
tometry (ACB) technique and compared them with healthy volunteers.
Methods. Ten renal transplant recipients and 10 healthy volunteers were enrolled in this
study. After an overnight fast, patients and volunteers ingested a standard meal containing
magnetic markers. The biomagnetic monitoring was performed at 10-minute intervals for
at least 8 hours to obtain gastric emptying as well as the colonic arrival time–intensity
curves. Mean gastric emptying time (MGET), mean colon arrival time (MCAT), and mean
small intestinal transit time (MSITT) were quantified and compared between control and
patient groups with results expressed as mean  SD.
Results. The MGET measured by the ACB technique was 48  31 minutes and 197  50
minutes for patients and healthy subjects, respectively. MSITT and MCAT values calculated
for patients versus volunteers were 171  71 minutes versus 197  71 minutes and 219  83
minutes versus 373 52 minutes, respectively. Renal transplant recipients showed significantly
faster; gastric emptying and colon arrival times (P  .001) compared with normal volunteers;
however, small intestinal transit time was not significantly different (P  .44).
Conclusions. In stable renal transplant recipients, the GI transit parameters were
significantly faster than in normal healthy volunteers. ACB sensors are versatile technol-
ogies that can be used for clinical research, because they offer an excellent opportunity to
evaluate GI transit in a noninvasive manner without the use of ionizing radiation.
l
dGastrointestinal (GI) complications are frequently re-ported as a common adverse effect after kidney
transplantation.1 Mechanical injury during surgery, meta-
bolic changes associated with transplantation, infectious
agents, endogenous GI dysfunction, and organ toxicity of
immunosuppressive agents may contribute to GI distur-
bances.2,3 Nevertheless, GI motility disorders after renal
transplantation are not well studied.
In clinical practice, radiography, manometry, and scintig-
raphy remain the most important investigational techniques
toward evaluating GI motility disorders.4 However, the
osts associated with equipment and materials, radiation
xposure, licensing for handling radioactive materials, and
pproval by appropriate institutional committees, as well as
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2384imited temporal and spatial resolution, are some of the
rawbacks.
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AC BIOSUSCEPTOMETRY IN RENAL TRANSPLANT RECIPIENTS 2385Nowadays, alternative techniques based on biomagnetic
field detection have been developed for GI motility stud-
ies.5–7 alternate current biosusceptometry (ACB) is a non-
nvasive and radiation-free technique that uses induction
oils to measure biomagnetic fields resulting from ferro-
agnetic sources in response to an applied magnetic
eld.8–11 With recent improvements in instrumental sensi-
ivity, its ease of use, and growing interest from diverse
elds, the magnetic sensors have been recognized as valu-
ble tools for biomedical, pharmaceutical, and clinical
pplications.
The aims of the present study were to examine the GI
ransit parameters in renal transplant recipients taking
acrolimus, azathioprine, and prednisone as immunosup-
ressive therapy with the use of the ACB technique and to
ompare the results with those in healthy volunteers.
METHODS
Instrumentation
Alternate current biosusceptometry works as a double magnetic
flux transformer with air nucleus. A single-sensor ACB is composed
of pairs of induction coils separated by a fixed baseline.8,11 Each
pair of coils consists of excitation (outer) and detection (inner)
coils in a first-order gradiometric relationship. The excitation coil
generates a magnetic field and induces equal magnetic flux in the
detection coils; thus, when a ferromagnetic sample is the sensor, an
imbalance in the voltage occurs due to the changes in the differ-
ential flux between the detection coils. This biomagnetic sensor
measures the signals generated by the magnetic flux variation
between these coils through lock-in amplifiers. Additional technical
details have been reported earlier.11,12 Magnetic signals detected
by the ACB sensor depend on the surface area of the detection coil,
number of turns, rate of change of the magnetic flux (ie applied
field), amount of ferromagnetic material, and distances among the
sensors and the magnetic sample. This device does not need to be
operated in magnetically shielded rooms. The ferromagnetic ma-
terial remains inert and cannot be absorbed by the GI tract.
Subjects
The Ethics Committee of the Universidade Estadual de Ciências
da Saúde de Alagoas approved the study protocol, and trials were
conducted in accordance with the Declaration of Helsinki and its
revisions. Ten renal allograft recipients (8 men and 2 women, mean
age, 43  6.4 years; age range, 34–51 years; mean time after
transplantation, 78  33 months; [range, 31–117 months]) and 10
healthy volunteers (6 men and 4 women; mean age, 25  6.5 years;
age range, 20–38 years) who had signed informed consent were
enrolled in the study. All of the patients had stable renal function
and were receiving prednisone (PRED; Geolab, Brazil), azathio-
prine (AZA; Cristália, Brazil), and tacrolimus (FK506; Prograf,
Janssen-Cilag, Brazil) as triple immunosuppressive therapy. At the
time of the study, none of the subjects had a history of GI disease
or comedications that might affect the GI motor function.
Biomagnetic Measurements and Data Analysis
The GI transit study was performed in the morning after an
overnight fast. Subjects consumed a standard 420-kcal breakfast
(bread, ham, cheese, 300 mL orange juice). Five minutes after
eating, the subjects ingested the magnetic markers, consisting of 4hard gelatin capsules (size 00) filled with 1.50 g ferrite powder (53
   75 m; Imag, Brazil) with 200 mL of water, and the
iomagnetic monitoring was started immediately. A single-sensor
CB was used to monitor a square point matrix (5  5) drawn
round the gastric and colonic regions. Each monitoring had 120
econds duration and was recorded at 10-minutes intervals for at
east 8 hours to obtain the magnetic field distribution. These
atrices were mathematically interpolated and processed to obtain
equential images.12,13 Gastric emptying as well as the colonic
rrival time–intensity curves were obtained. The statistical moment
as obtained through the temporal average pondered by time-
ntensity curves, normalized by area under curve.14 By using this
pproach, the following GI transit parameters were calculated:
ean gastric emptying time (MGET), defined as the amount of
agnetic material that emptied from the stomach at time t (min)
nd was calculated by the area under emptying curve; mean colon
rrival time (MCAT), defined as the increase of amount of
agnetic material that arrived in colon at time t (min) and
alculated by the area between cecum arrival curve until maximal
umulative values; mean small intestinal transit time (MSITT),
uantified as the difference between MCAT and MGET. All the
esults were expressed as mean  SD. Values of MGET, MCAT,
nd MSITT were compared between the control and patient
roups with the use of the unpaired Student t test. A P value
f .05 was considered to be statistically significant. All signals and
mages were analyzed in Matlab (Mathworks, USA) and Origin
Origin Lab, USA).
RESULTS
Demographics, transplantation-related characteristics, allo-
graft function, and the GI transit parameters for both
groups are summarized in Table 1.
The MGET measured by the ACB technique was 48
minutes (range, 15–118) and 197 minutes (range, 71–278)
for patients and healthy subjects, respectively. MSITT and
MCAT values calculated for patients versus control volun-
teers were 171 minutes (107–218) versus 197 minutes
(71–278) and 219 minutes (122–346) versus 373 minutes
(271–448), respectively. In the renal transplant recipients,
gastric emptying and colon arrival time were significantly
Table 1. Demographic and Laboratory Data as Well as
Gastrointestinal Transit Time Parameters of Renal Transplant
Patients and Healthy Control Subjects
Patients
(n  10)
Control Subjects
(n  10)
Age, y 43  6.5 24  5
ex (male/female) 8/2 5/5
ime of transplantation, mo 78  33 N/A
erum creatinine (mg/dL) 1.4  0.3 N/A
reatinine clearance (mL/min) 66  15 N/A
erum concentration of FK506
(ng/mL)
5.3  1.6 N/A
MGET (min) 48  31* 177  50*
SITT (min) 171  71† 197  71†
MCAT (min) 219  83* 373  52*
Data are expressed as mean  SD. FK506, tacrolimus; MGET, mean gastric
emptying time; MSITT, mean small intestinal transit time; MCAT, mean colon
arrival time.
*P  .001; †P  .44.
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2386 TEIXEIRA, MAGALHÃES, GALVÃO ET ALfaster (P  .001) compared with normal volunteers; how-
ver, small intestinal transit time was not significantly
ifferent (P  .44; Fig 1). Figure 2 depict the gastric
mptying profiles for 2 representative subjects.
Fig 1. Postprandial gastrointestinal transit parameters evalu-
ated for renal transplant recipients and healthy volunteers. Mean
gastric emptying time (MGET) and colon arrival time (MCAT)
were significantly faster (P  .001) for patients group compared
with control subjects. Small intestinal transit time (MSITT) was
not significantly different (P  .44).
Fig 2. Gastric emptying profiles
obtained in a patient (solid line)
and in a healthy volunteer (dash
line). Arrows indicate the mean
times for gastric emptying.DISCUSSION
The choice of maintenance immunosuppressive therapy
after renal transplantation to prevent allograft rejection is
not devoid of side effects.15 Despite GI complications often
being associated with immunosuppressive regimens, motil-
ity disorders have been scantily studied after renal trans-
plantation.1,16 Few studies have assessed GI transit in
atients treated with immunosuppressive agents such as
yclosporine, FK506, mycophenolate, or sirolimus.17–19
Furthermore, all of those studies were performed with
the use of scintigraphy or 13C breath tests. Although those
echniques are not invasive, the main drawback of scinti-
raphic studies is radiation exposure, which makes it less
cceptable when repeated evaluations are necessary.4,20
The 13C breath tests use ingestion of stable isotopes and
etection of exhaled 13CO2 as an indirect measurement of
astric emptying and transit time. Although the results are
imilar to those obtained with the gold standard, the high
osts of producing 13C-labeled meals is high. Moreover, a
ass spectrometer, which is needed to analyze the samples,
s expensive.21
To overcome such technical shortcomings, alternate
methods based on biomagnetic field detection have been
developed. ACB is a noninvasive and radiation-free tech-
nique currently available for monitoring a number of GI
physiologic parameters.10,13,22–24
In the present study, ACB was used for the first time to
evaluate GI transit parameters in renal transplant recipients
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AC BIOSUSCEPTOMETRY IN RENAL TRANSPLANT RECIPIENTS 2387taking triple maintenance immunosuppressive therapy com-
prising of PRED, AZA, and FK506. All of the patients
enrolled in the study had stable renal function, as presented
in Table 1. The results showed that gastric emptying and
colon arrival were significantly faster compared with normal
healthy volunteers (Fig 1). On the other hand, the MSITT
was quite consistent between the groups, although individ-
ual values varied widely. As reported earlier, small intesti-
nal transit time in humans seems to be relatively constant
and appears to be less influenced by prandial state, age, or
sex.25
Regarding our findings, it has been supposed that FK506
has a potential prokinetic effect on the GI transit parame-
ters. It is worth highlighting that FK506 is a macrolide and,
like all structurally related compounds, induces interdiges-
tive activity contraction (phase III), and this effect is
mediated by interaction with motilin receptors in the GI
tract.17,26 This pronounced effect may be observed in the
ean time needed to emptying the stomach when comparing
renal transplant recipient with a normal volunteer (Fig 2).
In summary, our data showed that in stable renal trans-
lant recipients, the GI transit parameters were significantly
aster compared with normal healthy volunteers. Notwith-
tanding, there are still gaps in our knowledge regarding
arious aspects concerning the role of maintenance immu-
osuppression therapy on GI motility in renal transplant
ecipients. ACB sensors are versatile technologies that can
e used for a wide range of applications. For clinical
esearch, this method offers an excellent opportunity to
valuate GI transit in a noninvasive manner without the use
f ionizing radiation.
REFERENCES
1. Ponticelli C, Colombo D, Novara M, et al: Gastrointestinal
symptoms impair quality of life in Italian renal transplant recipients
but are under-recognized by physicians. Transpl Int 23:1126, 2010
2. Ponticelli C, Passerini P: Gastrointestinal complications in
renal transplant recipients. Transpl Int 18:643, 2005
3. Helderman JH, Goral S: Gastrointestinal complications of
transplant immunosuppression. J Am Soc Nephrol 13:277, 2002
4. Smout AJPM, Mundt MW: Gastrointestinal motility testing.
Best Pract Res Clin Gastroenterol 23:287, 2009
5. Andrä W, Danan H, Kirmsse W, et al: A novel method for
real-time magnetic marker monitoring in the gastrointestinal tract.
Phys Med Biol 45:3081, 2000
6. Bradshaw LA, Irimia A, Sims JA, et al: Biomagnetic signa-
tures of uncoupled gastric musculature. Neurogastroenterol Motil
21:778, 2009
7. Weitschies W, Blume H, Mönnikes H: Magnetic marker
monitoring: high resolution real-time tracking of oral solid dosage
forms in the gastrointestinal tract. Eur J Pharm Biopharm 74:93,
2010
m
28. Baffa O, Oliveira RB, Miranda JRA, et al: Analysis and
development of an AC biosusceptometer for orocaecal transit time
measurements. Med Biol Eng Comput 33:353, 1995
9. Miranda JRA, Oliveira RB, Sousa PL, et al: A novel biomag-
netic method to study gastric antral contractions. Phys Med Biol
42:1791, 1997
10. Américo MF, Oliveira RB, Corá LA, et al: The ACB
technique: a biomagnetic tool for monitoring gastrointestinal con-
traction directly from smooth muscle in dogs. Physiol Meas 31:159,
2010
11. Corá LA, Américo MF, Oliveira RB, et al. Biomagnetic
methods: technologies applied to pharmaceutical research. Pharm
Res 28:438, 2011
12. Corá LA, Américo MF, Romeiro FG, et al: Pharmaceutical
applications of AC biosusceptometry. Eur J Pharm Biopharm
74:67, 2010
13. Miranda JRA, Corá LA, Américo MF, et al: AC biosuscep-
tometry technique to evaluate the gastrointestinal transit of pellets
under influence of prandial state. J Pharm Sci 99:317, 2010
14. Podczek F, Newton JM, Yuen KH: The description of the
gastrointestinal transit of pellets assessed by gama scintigraphy
using statistical moments. Pharm Res 12:376, 1995
15. Aw MM. Transplant immunology. J Pediatr Surg 38:1275,
2003
16. Kleinman L, Faull R, Walker R, et al: Gastrointestinal
specific patient reported outcome instruments differentiate be-
tween renal transplant patients with or without GI complications.
Transplant Proc 37:846, 2005
17. Maes BD, Vanwalleghem J, Kuypers D, et al: Differences in
gastric motor activity in renal transplant recipients treated with
FK-506 versus cyclosporine. Transplantation 68:1482, 1999
18. Ozkaya O, Derici U, Buyan N, et al: Gastric emptying time
in renal transplant recipients treated with cyclosporine. Transplant
Proc 35:2927, 2003
19. Maes BD, Evenepoel P, Kuypers D, et al: Influence of SDZ
RAD vs MMF on gastric emptying in renal transplant recipients.
Clin Transplant 17:171, 2003
20. Rao SSC, Camilleri M, Hasler WL, et al: Evaluation of
gastrointestinal transit in clinical practice: position paper of the
American and European Neurogastroenterology and Motility So-
cieties. Neurogastroenterol Motil 23:8, 2011
21. Savarino V, Vignerib S, Celle G: The 13C urea breath test in
he diagnosis of Helicobacter pylori infection. Gut 45:I18, 1999
22. Romeiro FG, Corá LA, Andreis U, et al: A novel biomag-
etic approach to study caecocolonic motility in humans. Neuro-
astroenterol Motil 18:1078, 2006
23. Américo MF, Oliveira RB, Romeiro FG, et al: Scintigraphic
alidation of AC Biosusceptometry to study the gastric motor
ctivity and the intragastric distribution of food in humans. Neu-
ogastroenterol Motil 19:804, 2007
24. Américo MF, Marques RG, Zandona EA, et al: Validation
f ACB in vitro and in vivo as a biomagnetic method for measuring
tomach contraction. Neurogastroenterol Motil 22:1340, 2010
25. Yuen K-H: The transit of dosage forms through the small
ntestine. Int J Pharm 395:9, 2010
26. Feighner SD, Tan CP, McKee KK, et al: Receptor for
otilin identified in the human gastrointestinal system. Science
84:2184, 1999
